168 related articles for article (PubMed ID: 38058821)
21. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma.
Jiang X; Li Y; Zhang N; Gao Y; Han L; Li S; Li J; Liu X; Gong Y; Xie C
Cell Biosci; 2021 Apr; 11(1):74. PubMed ID: 33858512
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
23. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
[TBL] [Abstract][Full Text] [Related]
24. Association of
Jia M; Yao L; Yang Q; Chi T
Front Oncol; 2020; 10():168. PubMed ID: 32154170
[TBL] [Abstract][Full Text] [Related]
25. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
[TBL] [Abstract][Full Text] [Related]
26. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
[TBL] [Abstract][Full Text] [Related]
27. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
28. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
Wang N; Zhu L; Xu X; Yu C; Huang X
Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
[TBL] [Abstract][Full Text] [Related]
29. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
30. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
[TBL] [Abstract][Full Text] [Related]
31. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
[TBL] [Abstract][Full Text] [Related]
32. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
33. MiR-202-3p inhibits the proliferation and metastasis of lung adenocarcinoma cells by targeting RRM2.
Cao X; Xue F; Chen H; Shen L; Yuan X; Yu Y; Zong Y; Zhong L; Huang F
Ann Transl Med; 2022 Dec; 10(24):1374. PubMed ID: 36660663
[TBL] [Abstract][Full Text] [Related]
34. Screening and validation of plasma cell-derived, purinergic, and calcium signalling-related genetic signature to predict prognosis and PD-L1/PD-1 blockade responses in lung adenocarcinoma.
Huang J; Fan X; Hu B; Chen L
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12931-12945. PubMed ID: 37468608
[TBL] [Abstract][Full Text] [Related]
35. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
36. Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma.
Xia Z; Rong X; Dai Z; Zhou D
Front Genet; 2022; 13():863796. PubMed ID: 35571056
[No Abstract] [Full Text] [Related]
37. Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis.
Hu ZY; Huang WY; Zhang L; Huang B; Chen SC; Li XL
Ann Transl Med; 2020 Sep; 8(18):1172. PubMed ID: 33241021
[TBL] [Abstract][Full Text] [Related]
38. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
39. Independent prognostic implications of
Ma C; Luo H; Cao J; Gao C; Fa X; Wang G
J Cancer; 2020; 11(23):7009-7022. PubMed ID: 33123291
[No Abstract] [Full Text] [Related]
40. Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma.
Ma K; Qiao Y; Wang H; Wang S
Ann Transl Med; 2020 Nov; 8(22):1478. PubMed ID: 33313223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
